Live attenuated and inactivated influenza vaccines in children

Journal of Infectious Diseases

Volumn 211, Issue 3, 2015, Pages 352-360

  Ilyushina, Natalia A ^a   Haynes, Brenda C ^a   Hoen, Anne G ^b   Khalenkov, Alexey M ^a   Housman, Molly L ^a   Brown, Eric P ^c   Ackerman, Margaret E ^c   Treanor, John J ^d   Luke, Catherine J ^e   Subbarao, Kanta ^e   Wright, Peter F ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Department of Community and Family Medicine ^*  (United States)

^c DARTMOUTH COLLEGE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

children; influenza; vaccines

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; IMMUNOGLOBULIN A; INACTIVATED VACCINE; LIVE VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

AGE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTUMN; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; LOADING DRUG DOSE; MALE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SCHOOL CHILD; VACCINATION REACTION; VIRUS HEMAGGLUTINATION; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS SHEDDING; ANTIBODY PRODUCTION; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; PRESCHOOL CHILD; PROCEDURES;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84922513784     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu458     Document Type: Article

References (21)

1. Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011; 29: 9159-70.
2. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338:1405-12.
3. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
4. Ashkenazi S, Vertruyen A, Aristequi J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pe-diatr Infect Dis J 2006; 25:870-9.
5. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9.
6. Palmer DF, Dowdle WR, Coleman MT, Schild GC. Advanced laboratory techniques for influenza diagnosis. In: US Department of Health, Education, and Welfare, immunology series. No. 6. Atlanta, GA: Centers for Disease Control, 1975.
7. Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999; 18:82-8.
8. Shchrebik S, Sergent SB, Davis WG, et al. Application of real-time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production. J Virol Methods 2014; 195:18-25.
9. Wright PF, Bhargava M, Johnson PR, Thompson J, Karzon DT. Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes. Vaccine 1985; 3:305-8.
10. Clements ML, Betts RF, Tierney EL, Murphy BR. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986; 23:73-6.
11. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157-60.
12. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 2000; 18:899-906.
13. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986; 154:121-7.
14. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204: 845-53.
15. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133-7.
16. Katayose M, Hosoya M, Haneda T, et al. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine 2011; 17:1844-9.
17. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5:67-75.
18. Renegar KB, Small PA, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173:1978-86.
19. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006; 80:11756-66.
20. Fleet WF, Couch RB, Cate TR, Knight V. Homologous and heterologous resistance to rhinovirus common cold. Am J Epidemiol 1965; 82: 185-96.
21. Smith CB, Purcell RH, Bellanti JA, Chanock RM, Laine P. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966; 275: 1145-52.